Roivant Sciences Ltd.

DB:87S Stock Report

Market Cap: €8.0b

Roivant Sciences Valuation

Is 87S undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 87S when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 87S's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 87S's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 87S?

Key metric: As 87S is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 87S. This is calculated by dividing 87S's market cap by their current earnings.
What is 87S's PE Ratio?
PE Ratio1.8x
EarningsUS$4.60b
Market CapUS$8.37b

Price to Earnings Ratio vs Peers

How does 87S's PE Ratio compare to its peers?

The above table shows the PE ratio for 87S vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average16.7x
BIO3 Biotest
14.9x29.3%€1.3b
FYB Formycon
14.2x30.6%€905.8m
2INV 2invest
13.4xn/a€67.3m
1SXP SCHOTT Pharma KGaA
24.5x15.7%€3.7b
87S Roivant Sciences
1.8x-58.7%€8.4b

Price-To-Earnings vs Peers: 87S is good value based on its Price-To-Earnings Ratio (1.8x) compared to the peer average (16.7x).

Price to Earnings Ratio vs Industry

How does 87S's PE Ratio compare vs other companies in the European Biotechs Industry?

6 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.27.5x42.1%
87S Roivant Sciences
 1.8x-58.7%US$8.37b
87S 1.8xIndustry Avg. 27.5xNo. of Companies5PE020406080100+
6 CompaniesEstimated GrowthMarket Cap
Industry Avg.27.5x42.1%
87S Roivant Sciences
 1.8x-58.7%US$8.37b
No more companies

Price-To-Earnings vs Industry: 87S is good value based on its Price-To-Earnings Ratio (1.8x) compared to the European Biotechs industry average (27.6x).

Price to Earnings Ratio vs Fair Ratio

What is 87S's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

87S PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio1.8x
Fair PE Ratio6x

Price-To-Earnings vs Fair Ratio: 87S is good value based on its Price-To-Earnings Ratio (1.8x) compared to the estimated Fair Price-To-Earnings Ratio (6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 87S forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€10.50
€15.49
+47.6%
11.5%€17.16€11.92n/a6
Dec ’25€11.38
€15.35
+35.0%
10.7%€17.05€11.84n/a7
Nov ’25€10.28
€15.67
+52.4%
13.9%€20.35€11.56n/a9
Oct ’25€9.92
€15.26
+53.8%
13.9%€19.81€11.25n/a9
Sep ’25€10.59
€15.19
+43.5%
14.7%€20.05€10.93n/a9
Aug ’25€9.55
€15.70
+64.3%
14.7%€20.31€11.08n/a9
Jul ’25€9.41
€15.53
+65.1%
12.5%€18.52€11.11n/a9
Jun ’25€9.14
€15.36
+68.2%
13.0%€18.44€11.06n/a9
May ’25€9.77
€15.13
+54.9%
14.0%€18.82€11.29n/a10
Apr ’25€9.20
€14.87
+61.6%
18.2%€21.01€10.96n/a11
Mar ’25€10.20
€14.91
+46.2%
19.4%€21.44€11.19n/a11
Feb ’25€9.00
€14.81
+64.5%
19.5%€21.02€10.97n/a10
Jan ’25€9.85
€14.37
+45.9%
20.4%€21.10€10.09n/a9
Dec ’24€8.40
€14.37
+71.1%
21.5%€20.99€10.04€11.388
Nov ’24€8.10
€15.55
+92.0%
17.0%€21.75€11.35€10.289
Oct ’24€12.00
€15.49
+29.1%
18.0%€21.76€11.35€9.928
Sep ’24€10.20
€14.55
+42.7%
19.8%€21.08€11.00€10.598
Aug ’24€10.50
€14.20
+35.2%
21.0%€20.73€9.92€9.558
Jul ’24€8.70
€14.11
+62.2%
20.9%€21.16€10.12€9.419
Jun ’24€8.15
€13.00
+59.5%
17.5%€17.64€9.28€9.148
May ’24€7.35
€12.88
+75.3%
18.3%€17.96€9.46€9.778
Apr ’24€6.40
€12.88
+101.3%
18.3%€17.96€9.46€9.208
Mar ’24€7.27
€12.41
+70.7%
20.6%€17.79€9.36€10.208
Feb ’24€7.29
€12.11
+66.2%
21.7%€17.54€9.23€9.008
Jan ’24€7.05
€11.51
+63.3%
27.6%€17.86€7.52€9.858
Dec ’23€4.91
€10.74
+118.8%
37.5%€18.35€6.76€8.408

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 12:33
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Roivant Sciences Ltd. is covered by 16 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Chi Meng FongBofA Global Research
Louise ChenCantor Fitzgerald & Co.